<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/04/PT-02-04-2026-shutterstock_1836507013-430x241.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="430" height="241" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/04/PT-02-04-2026-shutterstock_1836507013-430x241.jpg"/></p>
<p>此次合作旨在支持新型抗体治疗药物，并加速有前景的分子进入临床和商业阶段。图片来源：Michele Ursi / Shutterstock.com。</p>
<p>百奥赛图已与四环医药达成战略合作，以推动多个疾病领域的新疗法，包括减肥。</p>
<p>根据协议，百奥赛图的全人源抗体发现平台将与四环医药在药物开发、生产和商业化方面的能力相结合。</p>
<h3>深入了解 GlobalData</h3>
<ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<p>报告</p>
<h4>LOA 和 PTSR 模型 - BI-907828 在去分化脂肪肉瘤中的应用</h4>
<ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<p>报告</p>
<h4>LOA 和 PTSR 模型 - BI-907828 在肺腺癌中的应用</h4>
<h5>深入了解 GlobalData</h5>
<p>商业智能的黄金标准。</p>
<p>了解更多</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></p>
<h4>发现高效的 B2B 营销</h4>
<p>结合商业智能和编辑卓越，覆盖 36 个领先媒体平台的专业人士。</p>
<p>了解更多</p>
<p>此次合作将专注于多个疾病领域的先进疗法，包括减肥，利用公司的互补能力支持开发和潜在市场进展。</p>
<p>百奥赛图将利用其综合平台，包括体内有效性系统、靶向人源化小鼠模型和基于 AI 的抗体发现平台，这些平台是基于真实人类抗体序列开发的。</p>
<p>这种方法旨在支持新型抗体治疗药物的开发，并加速有前景的分子进入临床和商业阶段。</p>
<p>百奥赛图总裁兼首席执行官沈跃雷博士表示：“我们很高兴与四环医药建立这一战略合作关系。</p>
<p>“此次合作将进一步扩大我们在多种疾病领域的联合努力，并进一步展示我们技术平台在行业中的强大认可。”</p>
<p>百奥赛图专注于利用基因编辑技术研发基于抗体的药物。</p>
<p>该公司建立了一个双引擎平台，结合了全人源抗体库和靶向人源化小鼠模型组合，以支持全球药物发现和开发。</p>
<p>通过其 RenSuper Biologics 子品牌，百奥赛图还提供了一个现成的库，包含超过一百万个针对 1000 多个靶点的全人源抗体序列。</p>
<p>在 2024 年 1 月，百奥赛图与 Radiance Biopharma 签署了独家选择和许可协议，用于双特异性抗体药物偶联物（BsADC）。</p>

华夏中证生物科技主题ETF

华夏医药ETF

百奥赛图-B

<p>百奥赛图已与四环医药建立合作关系，共同开发新疗法，重点关注减肥及其他疾病领域。此次合作将百奥赛图的人类抗体发现平台与四环的药物开发和商业化专业知识相结合。该战略联盟旨在加速有前景的抗体疗法的临床和商业进展，利用先进技术和综合平台。百奥赛图首席执行官沈跃雷博士对这一合作表示热情，强调其在药物发现和开发方面增强双方共同努力的潜力</p>

<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/04/PT-02-04-2026-shutterstock_1836507013-430x241.jpg" alt="" original-src="https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/04/PT-02-04-2026-shutterstock_1836507013-430x241.jpg"/></p>
<p>The collaboration is intended to support new antibody therapeutics and accelerate promising molecules towards clinical and commercial stages. Credit: Michele Ursi / Shutterstock.com.</p>
<div class="lb-trans"><p>此次合作旨在支持新型抗体治疗药物，并加速有前景的分子进入临床和商业阶段。图片来源：Michele Ursi / Shutterstock.com。</p>
</div><p>Biocytogen has entered a strategic partnership with Sihuan Pharmaceutical to advance new therapeutics across several disease areas, including weight loss.</p>
<div class="lb-trans"><p>百奥赛图已与四环医药达成战略合作，以推动多个疾病领域的新疗法，包括减肥。</p>
</div><p>Under the agreement, Biocytogen’s fully human antibody discovery platform will be combined with Sihuan Pharmaceutical’s capabilities in drug development, manufacturing, and commercialisation.</p>
<div class="lb-trans"><p>根据协议，百奥赛图的全人源抗体发现平台将与四环医药在药物开发、生产和商业化方面的能力相结合。</p>
</div><h3>Go deeper with GlobalData</h3>
<div class="lb-trans"><h3>深入了解 GlobalData</h3>
</div><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<div class="lb-trans"><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
</div><p>Reports</p>
<div class="lb-trans"><p>报告</p>
</div><h4>LOA and PTSR Model - BI-907828 in Dedifferentiated Liposarcoma</h4>
<div class="lb-trans"><h4>LOA 和 PTSR 模型 - BI-907828 在去分化脂肪肉瘤中的应用</h4>
</div><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<div class="lb-trans"><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
</div><p>Reports</p>
<div class="lb-trans"><p>报告</p>
</div><h4>LOA and PTSR Model - BI-907828 in Lung Adenocarcinoma</h4>
<div class="lb-trans"><h4>LOA 和 PTSR 模型 - BI-907828 在肺腺癌中的应用</h4>
</div><h5>Go deeper with GlobalData</h5>
<div class="lb-trans"><h5>深入了解 GlobalData</h5>
</div><p>The gold standard of business intelligence.</p>
<div class="lb-trans"><p>商业智能的黄金标准。</p>
</div><p>Find out more</p>
<div class="lb-trans"><p>了解更多</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg" alt="" original-src="https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></p>
<h4>Discover B2B Marketing That Performs</h4>
<div class="lb-trans"><h4>发现高效的 B2B 营销</h4>
</div><p>Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.</p>
<div class="lb-trans"><p>结合商业智能和编辑卓越，覆盖 36 个领先媒体平台的专业人士。</p>
</div><p>Find out more</p>
<div class="lb-trans"><p>了解更多</p>
</div><p>The collaboration will focus on advanced therapies in multiple disease areas, including weight loss, using the companies’ complementary capabilities to support development and potential market progress.</p>
<div class="lb-trans"><p>此次合作将专注于多个疾病领域的先进疗法，包括减肥，利用公司的互补能力支持开发和潜在市场进展。</p>
</div><p>Biocytogen will utilise its integrated platforms, including in vivo efficacy systems, target-humanised mouse models, and an AI-based antibody discovery platform developed from real human antibody sequences.</p>
<div class="lb-trans"><p>百奥赛图将利用其综合平台，包括体内有效性系统、靶向人源化小鼠模型和基于 AI 的抗体发现平台，这些平台是基于真实人类抗体序列开发的。</p>
</div><p>This approach is intended to support the development of new antibody therapeutics and accelerate promising molecules towards clinical and commercial stages.</p>
<div class="lb-trans"><p>这种方法旨在支持新型抗体治疗药物的开发，并加速有前景的分子进入临床和商业阶段。</p>
</div><p>Biocytogen president and CEO Dr Yuelei Shen said: “We are pleased to establish this strategic partnership with Sihuan Pharmaceutical.</p>
<div class="lb-trans"><p>百奥赛图总裁兼首席执行官沈跃雷博士表示：“我们很高兴与四环医药建立这一战略合作关系。</p>
</div><p>“This collaboration will further expand our joint efforts across diverse disease areas and further demonstrate strong industry recognition of our technology platforms.”</p>
<div class="lb-trans"><p>“此次合作将进一步扩大我们在多种疾病领域的联合努力，并进一步展示我们技术平台在行业中的强大认可。”</p>
</div><p>Biocytogen is focused on the research and development of antibody-based drugs using gene editing technology.</p>
<div class="lb-trans"><p>百奥赛图专注于利用基因编辑技术研发基于抗体的药物。</p>
</div><p>The company has established a dual-engine platform that combines a fully human antibody library with a target-humanised mouse model portfolio to support global drug discovery and development.</p>
<div class="lb-trans"><p>该公司建立了一个双引擎平台，结合了全人源抗体库和靶向人源化小鼠模型组合，以支持全球药物发现和开发。</p>
</div><p>Through its RenSuper Biologics sub-brand, it also offers an off-the-shelf library of more than a million fully human antibody sequences against over 1,000 targets.</p>
<div class="lb-trans"><p>通过其 RenSuper Biologics 子品牌，百奥赛图还提供了一个现成的库，包含超过一百万个针对 1000 多个靶点的全人源抗体序列。</p>
</div><p>In January 2024, Biocytogen and Radiance Biopharma signed an exclusive option and licence agreement for a bispecific antibody-drug conjugate (BsADC).</p>
<div class="lb-trans"><p>在 2024 年 1 月，百奥赛图与 Radiance Biopharma 签署了独家选择和许可协议，用于双特异性抗体药物偶联物（BsADC）。</p>
</div>

百奥赛图与四环医药合作推进减肥新疗法的研发